UTULY™
Treatment of severe allergic reactions (Type I), including anaphylaxis
Phase 3Active
Key Facts
Indication
Treatment of severe allergic reactions (Type I), including anaphylaxis
Phase
Phase 3
Status
Active
Company
About Bryn Pharma
Bryn Pharma is a clinical-stage biotech developing UTULY™, an intranasal spray formulation of epinephrine for anaphylaxis. The company aims to disrupt the established auto-injector market (e.g., EpiPen) by offering a needle-free, compact, and easy-to-administer option that could improve patient compliance and portability. Having completed a successful Phase 3 trial, Bryn is preparing for a New Drug Application (NDA) submission to the FDA. Its success hinges on regulatory approval, market adoption against entrenched competitors, and demonstrating clear advantages in usability and pharmacokinetics.
View full company profile